title: Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation.
abstract: Adoptive immune cell therapy represents one of the most promising fields of investigation in allogeneic haematopoietic stem cell transplantation (allo-HSCT). Preliminary studies indicate that adoptive immune cell therapy can be used to restore the immunocompetence of allo-HSCT recipients towards widespread pathogens in the early post-transplant period. These strategies can be of fundamental importance in patients given a T-cell-depleted allograft, a type of transplant that has been performed increasingly over the last few years. A few seminal studies have recently documented that prevention/treatment of Epstein-Barr-virus-related lymphoproliferative disorders, human cytomegalovirus disease and invasive aspergillosis can be obtained through infusion of pathogen-specific T-cell lines or clones. Several efforts are also being directed towards the identification of strategies capable of selecting and/or strengthening specific graft-vs-leukaemia responses. In this regard, strategies of ex-vivo generation and expansion of clones or cell lines, specifically or preferentially leukaemia reactive, have been developed.
authors.affiliation: Paediatric Haematology and Oncology, IRCCS Policlinico San Matteo, P.le Golgi, 2, 27100 Pavia, Italy. f.locatelli@smatteo.pv.it
authors.forename: Franco
authors.initials: F
authors.lastname: Locatelli
authors.forename: Patrizia
authors.initials: P
authors.lastname: Comoli
authors.forename: Daniela
authors.initials: D
authors.lastname: Montagna
authors.forename: Francesca
authors.initials: F
authors.lastname: Rossi
authors.forename: Liane
authors.initials: L
authors.lastname: Daudt
authors.forename: Rita
authors.initials: R
authors.lastname: Maccario
mesh_terms: D002648:Child; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007938:Leukemia / Q000150:complications / Q000628:therapy; D009894:Opportunistic Infections / Q000517:prevention & control / Q000628:therapy; D055502:Secondary Prevention